Leveraging cDC1 biology and function for enhanced immunotherapy
Journal of Experimental Medicine · 06.07.2026 · 223 (7)
DOI: 10.1084/jem.20241199 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, online erschienen am 10.06.2026. Verfasst von Ross W Ward und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 170 Literaturangaben. Gefördert von: Icahn School of Medicine at Mount Sinai, American Cancer Society.
Abstract (Originalsprache)
Conventional type 1 dendritic cells (cDC1s) promote antitumor immunity through efficient cross-presentation of tumor antigens and production of key mediators. Crucially, in the tumor microenvironment, cDC1s orchestrate immune hubs and signaling axes that support T cell responses and are associated with improved patient outcomes. During tumor progression, however, cDC1 activity is increasingly constrained by immunosuppressive signals and inhibitory cellular interactions. Many immunotherapies, including immune checkpoint blockade and adoptive cell transfer, depend on functional cDC1 populations for optimal efficacy, underscoring the need to define both the mechanisms that enable cDC1-mediated immunity and those that suppress it. Emerging strategies aim to harness cDC1s by expanding their numbers, reprogramming suppressed DC states, or strengthening interactions with CD8+ and CD4+ T cells and natural killer cells. Here, we discuss the molecular pathways, cellular phenotypes, and spatial features that govern cDC1 function, highlight the prognostic and predictive value of cDC1-associated signatures, and evaluate therapeutic approaches that leverage cDC1 biology to improve cancer treatment and durability of response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology & Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA.
ORCID-Profile: Ross W Ward, Uddipan Kar, Sreekumar Balan, Nina Bhardwaj
Förderung
- Icahn School of Medicine at Mount Sinai
- American Cancer Society
Zitieren
APA
Ward, R. W., Kar, U., Balan, S., & Bhardwaj, N. (2026). Leveraging cDC1 biology and function for enhanced immunotherapy. Journal of Experimental Medicine, 223(7). https://doi.org/10.1084/jem.20241199
Vancouver
Ward RW, Kar U, Balan S, Bhardwaj N. Leveraging cDC1 biology and function for enhanced immunotherapy. Journal of Experimental Medicine. 2026;223(7). doi:10.1084/jem.20241199
BibTeX
@article{Ward2026,
author = {Ward, Ross W and Kar, Uddipan and Balan, Sreekumar and Bhardwaj, Nina},
title = {Leveraging cDC1 biology and function for enhanced immunotherapy},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {7},
doi = {10.1084/jem.20241199}
}
EUVIMED